Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of
 single doses of BMS-686117
Inclusion Criteria:

 -  Diagnosis of Type 2 diabetes for ≥ 3 months treated with metformin, thiazolidinedione,
 or sulfonylurea (either monotherapy or combination) or diet alone (drug naïve)

 -  Fasting plasma glucose: 126 - 240 mg/dL

 -  Hemoglobin A1c: 6 - 10%

 -  Estimated CrCl ≥ 60 mL/min

 -  ALT ≤ 1.5 x ULN and total bilirubin ≤ 2 x ULN

 -  Stable and well controlled hypertension and/or dyslipidemia

 -  Concomitant medications used for hypertension and/or dyslipidemia, thyroid hormone
 replacement therapy and low dose aspirin will be allowed if stable for at least 6
 weeks

 Exclusion Criteria:

 -  Women of childbearing potential

 -  Symptomatic diabetes with polyuria and/or polydipsia

 -  History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome

 -  History of renal disease including diabetic nephropathy